{"news_desk": "Business", "print_page": "1", "section_name": "Business Day", "subsection_name": null, "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Biogen Idec presents results of small Phase 1 trial of experimental Alzheimer's disease drug aducanumab in Nice, France, which suggest drug can sharply slow decline in mental function in patients; results, if replicated in larger studies, will revive hope for pharmaceutical approach to therapy that has long been elusive.", "type_of_material": "News", "word_count": "999", "lead_paragraph": "The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials.", "pub_date": "2015-03-21T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Biogen Reports Its Alzheimer\u2019s Drug Sharply Slowed Cognitive Decline", "print_headline": "Alzheimer\u2019s Drug Shows Promise in a Trial"}, "snippet": "The drug, developed by Biogen Idec, could achieve sales of billions of dollars a year if the results from the small trial are replicated in larger trials.", "multimedia": [{"height": 126, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 453, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "453", "xlarge": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/03/21/business/21alzheimer-web/21alzheimer-web-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/03/21/business/alzheimers-drug-trial-shows-cognitive-decline-sharply-slowed.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Alzheimer's Disease", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Biogen Idec Inc", "name": "organizations"}, {"rank": "3", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Clinical Trials", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Dementia", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Eli Lilly and Company", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Johnson & Johnson", "name": "organizations"}, {"rank": "8", "is_major": "N", "value": "Pfizer Inc", "name": "organizations"}, {"rank": "9", "is_major": "N", "value": "Roche Holding AG", "name": "organizations"}, {"rank": "10", "is_major": "N", "value": "Nice (France)", "name": "glocations"}], "blog": [], "_id": "550be9be38f0d8631c7b12d4", "source": "The New York Times"}